Educational Sessions

We are bringing some of the CAPhO Conference 2020 sessions that were scheduled for our annual Conference last April to you virtually over two days.  One day of sessions will be on Saturday, June 13 and the other day of sessions will be Saturday, June 27 starting at 12:00 EDT. Not a member? Join CAPhO

Attend the June 13 and 27 educational sessions live to receive Continuing Education Credits from the Canadian Council on Continuing Education in Pharmacy (CCCEP).

Click on the links below to be directed to specific days: 

Saturday, June 13

Opening Remarks (12:00-12:10 EDT)

Top 5 Articles That Changed My Practice (12:10-12:50 EDT)

Scott Edwards, Dr. H. Bliss Murphy Cancer Centre, Newfoundland, NL
 
Oncology professionals are overwhelmed with ever-expanding volumes of new information. Despite that, only a small percentage of trials are significant enough to be practice changing. This talk will focus on 5 articles that have the potential to truly impact the practice of an oncology clinician. These articles will focus on current, evidence-based, practical information which an oncology professional can incorporate into their day-to-day practice. 
 
Learning Objectives:
  1. Apply takeaways from practice-changing articles of 2019-2020;
  2. Recognize some of the practical clinical issues from the recent literature; and
  3. Demonstrate an understanding of how to apply this new information in daily practice.

Q&A (12:50-13:00 EDT)

Break (13:00-13:10 EDT)

Welcome Back (13:10-13:15 EDT)

Biomarkers – Where Did We Come From, and Where Are We Going? (13:15-13:55 EDT)

Tom McFarlane, University of Waterloo / Sunnybrook Health Sciences, Toronto, ON
 
Oncology medicine is becoming increasingly personalized, and the mapping of the human genome has led to the uncovering of many potential targets which may allow us to direct therapeutic interventions in cancer patients. This session will define what makes a good biomarker, give historical perspective on biomarker use in cancer treatment, briefly discuss where we are in terms of the biomarkers available to us currently, and outline future directions for biomarker development and discovery.
 
Learning Objectives:
  1. Understand how the term biomarker is defined and the different types of biomarkers;
  2. Understand biomarkers within the context of cancer treatment and why personalized medicine is important;
  3. Identify biomarkers that have made a large clinical impact in oncology treatment; and
  4. Comprehend the directions we are taking with biomarkers and design of future clinical trials involving biomarkers.

Q&A (13:55-14:05 EDT)

Closing Remarks (14:05-14:10 EDT)

Back to top

Saturday, June 27

Opening Remarks (12:00-12:10 EDT)

Common Infections in the Ambulatory Malignant Hematology Patient Population (12:10-12:50 EDT)

Melissa Lo, Princess Margaret Cancer Centre, Toronto, ON
Samantha Polito, Princess Margaret Cancer Centre, Toronto, ON
 
Patients with a hematological malignancy often present with infectious complications. During their disease trajectory, it is estimated that 80% of these patients will experience an episode of febrile neutropenia; 70-80% of these episodes will not have an identifiable source. Others are found to be caused by a multitude of different infections. Management of these patients on an outpatient basis remains a major challenge for oncology pharmacists and the multidisciplinary health care team. In this presentation, we will review febrile neutropenia as an infectious syndrome, and discuss central line infections, lower respiratory tract infections (focusing on fungal pneumonia), and CMV mucositis as infections commonly seen in this patient population.
 
Learning Objectives:
 
  1. Identify malignant hematology patients most at risk for infectious complications in the ambulatory setting;
  2. Review Febrile Neutropenia as an infectious syndrome commonly seen in malignant hematology patients;
  3. Describe the management of central line infections, lower respiratory tract infections, and CMV mucositis in the ambulatory setting; and
  4. Discuss difficulties and potential risks of infection management in the ambulatory setting.

Q&A (12:50-13:00 EDT)

Break (13:00-13:10 EDT)

Welcome Back (13:10-13:15 EDT)

Implementing a New Oncology Electronic Health Record – Voices of Experience (13:15-13:55 EDT)

Catherine Bond-Mills, London Regional Cancer Program / Southwest Regional Cancer Program, London, ON
Lisa Rambout, Ottawa Hospital, Ottawa, ON

In the past few years there has been an increasing drive in the oncology space towards implementing Electronic Health Record (EHR) systems which will allow for Computerized Physician Order Entry (CPOE) and which bring all patient care systems together under one roof. The Ottawa Hospital (TOH) and London Health Sciences Centre (LHSC) have both adopted such systems; EPIC at TOH and Cerner Powerchart Oncology at LHSC. We aim to share our experiences and lessons learned in order to be helpful to other institutions which may be looking at similar implementations. 

Learning Objectives:

  1. Understand how EHR systems can add value to patient care in oncology settings;
  2. Understand how to prepare effectively for the changes associated with implementing a new EHR system;
  3. Understand how to survive going live; expectations versus reality during implementation; and
  4. Share lessons learned at TOH and LHSC in order to support other centres implementing EHR systems.

Q&A (13:55-14:05 EDT)

Break (14:05-14:15 EDT)

Improving Patient Safety through Adverse Event Reporting: What's Happening in Canada? (14:15-15:00 EDT)

Kathy Vu, Cancer Care Ontario, Toronto, Ontario
Thanh Vu, Health Canada, Vancouver, BC

Patient safety is a fundamental cornerstone of health care. Organizations all strive to set up systems and processes that will reduce the risk of adverse drug events (ADEs) for patients in their care.  An adverse drug event is an injury resulting from medical intervention related to a drug. This includes medication incidents, adverse drug reactions (ADRs), allergic reactions, and overdoses.1 ADEs can happen in a variety of places including hospitals, long-term care settings, and community settings.  This session will focus on two major components of ADEs: medication incidents and adverse drug reactions.
 
While it is estimated that ADRs account for up to two-thirds of drug-related hospital admissions and emergency department visits2, international studies estimate, on average, no more than 5% of serious ADRs detected by health care professionals are actually being reported3,4, and there is no evidence to suggest that Canadian reporting rates are higher. This suggests significant under-reporting of important therapeutic product information, which reduces Health Canada’s ability to identify, at an early stage, potential safety problems.
 
On December 16, 2019, new federal regulations came into effect requiring hospitals across the country to report serious adverse drug reactions and medical device incidents (MDIs) to Health Canada within 30 days of being documented within the hospital. The mandatory reporting regulations are designed to improve the reporting of a valuable source of information about the ‘real world’ experiences of patients and health care professionals using the drugs and devices on the Canadian market. Improved reporting will help Health Canada identify emerging safety issues with health products and take action when needed to protect patients. 
 
Under-reporting of medication incidents is also well described in Canada and globally.  This poses a significant problem for patient safety because incident learning and quality improvement initiatives are hindered by the lack of awareness and collaboration.  The Medication Safety Summit in 2014 resulted in a white paper outlining key recommendations to improve the quantity and quality of reporting.5 Since then, provinces across Canada have attempted to move these recommendations forward in different manners.  Mandatory incident reporting exists in some provinces while others have managed to develop a centralized repository for incident reporting to be analyzed provincially and shared nationally.
 
In oncology, most ADRs and medication incidents from systemic therapy are considered inevitable and decades of clinical expertise in oncology have allowed clinicians to effectively manage or prevent them. In this sense, the contribution of reporting has been, and continues to be, of paramount importance in recognizing the risks associated with delivering therapy. 
 
The importance of ADR and medication incident reporting in oncology cannot be overemphasized. Any improvements in drug safety knowledge and the process by which they flow through the medication management system will ultimately lead to improvements in safety and care, and offer patients with cancer every possible help to improve their quality of life during such a critical period of their lives

Learning Objectives:

  1. Distinguish adverse drug reactions (ADRs) from incident reporting (IR); 
  2. Explain the potential impact of ADRs and IR on population health;  
  3. Provide an overview of the mandatory reporting of serious ADRs and MDIs by hospitals requirement; 
  4. Provide an overview of incident reporting across Canada; and
  5. Discuss the challenges and opportunities of mandatory adverse drug reaction and incident reporting within the healthcare system.

Q&A (15:00-15:10 EDT)

Closing Remarks (15:10-15:15 EDT)